Heparin-induced Thrombocytopenia Clinical Trial
Official title:
A Phase II Study to Evaluate the Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
This research study is studying a drug as a possible treatment for heparin induced thrombocytopenia (HIT) or Heparin-induced Thrombocytopenia and Thrombosis (HITT). The drug involved in this study is apixaban.
This research study is a Phase II clinical trial. The FDA (the U.S. Food and Drug Administration) has not approved apixaban as a treatment option for this specific disease but it has been approved for other uses. HIT and HITT are common and severe complications of heparin therapy. Once patients are diagnosed with either one of these, they are typically switched to a non-heparin anticoagulant (a type of drug that thins your blood). As of now the only drug that is FDA approved for HIT or HITT is argatroban, which is administered continuously through an IV over multiple days and is extremely costly. In this research study, the investigators are researching the activity and tolerability of apixaban in participants with HIT or HITT. The investigators believe that apixaban will work just as well as argatroban and will be more convenient for this population. The oral route of apixaban allows for the potential outpatient treatment of HIT or HITT which is both convenient and less expensive than treatment with argatroban. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT00759083 -
Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients
|
Phase 4 | |
| Completed |
NCT00412464 -
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
|
Phase 1 | |
| Completed |
NCT00456326 -
Heparin-Induced Thrombocytopenia Registry
|
N/A | |
| Terminated |
NCT00673439 -
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
|
Phase 2 | |
| Active, not recruiting |
NCT00198575 -
A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients
|
N/A | |
| Completed |
NCT00283322 -
Heparin Antibodies in Intensive Care Unit Patients (HAICU)
|
N/A | |
| Not yet recruiting |
NCT05586854 -
Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia
|
N/A | |
| Not yet recruiting |
NCT03269019 -
Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia
|
N/A | |
| Not yet recruiting |
NCT06066762 -
Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
|
||
| Terminated |
NCT03809481 -
Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban
|
Phase 3 | |
| Completed |
NCT05325346 -
A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
|
Phase 1 | |
| Recruiting |
NCT02717039 -
Pharmacogenomics of Heparin-Induced Thrombocytopenia
|
||
| Completed |
NCT02526485 -
Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
|
||
| Completed |
NCT00748839 -
Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical
|
N/A | |
| Recruiting |
NCT05783895 -
Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery
|
||
| Not yet recruiting |
NCT04782843 -
Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care.
|
||
| Completed |
NCT00198588 -
Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia
|
Phase 3 | |
| Recruiting |
NCT04842760 -
PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
|
||
| Terminated |
NCT01598168 -
Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
|
Phase 3 | |
| Completed |
NCT01654848 -
Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients
|
N/A |